Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PPP2R4 Antibodies:
anti-Mouse (Murine) PPP2R4 Antibodies:
anti-Rat (Rattus) PPP2R4 Antibodies:
Go to our pre-filtered search.
Human Monoclonal PPP2R4 Primary Antibody for ICC, FACS - ABIN969557
Yoon, Jun, Park, Jun Yoo, Moon, Soon Baik, Kim, Kim, Kim, Koh, Taek Lee, You: Optimal suppression of protein phosphatase 2A activity is critical for maintenance of human embryonic stem cell self-renewal. in Stem cells (Dayton, Ohio) 2010
Show all 2 Pubmed References
Human Monoclonal PPP2R4 Primary Antibody for IP, WB - ABIN1042656
Fellner, Lackner, Hombauer, Piribauer, Mudrak, Zaragoza, Juno, Ogris: A novel and essential mechanism determining specificity and activity of protein phosphatase 2A (PP2A) in vivo. in Genes & development 2003
Human Polyclonal PPP2R4 Primary Antibody for ELISA, WB - ABIN4347103
Gushiken, Patel, Liu, Pradhan, Bergeron, Peng, Vijayan: Protein phosphatase 2A negatively regulates integrin alpha(IIb)beta(3) signaling. in The Journal of biological chemistry 2008
Study reveals the mechanism controlling abscission through integration of Aurora B kinase (show AURKB Antibodies) and B56-bound PP2A phosphatase activities on the kinesin motor protein (show KIF16B Antibodies) MKlp2 (show KIF20A Antibodies). MKlp2 (show KIF20A Antibodies) is an essential protein for promoting abscission, which may regulate tethering and stabilizing of the PM to the microtubule cytoskeleton at the intercellular bridge through its previously uncharacterized lipid association motif.
These results suggest that loss of specific PP2A regulatory subunits is functionally important in breast tumourigenesis, and support strategies to enhance PP2A activity as a therapeutic approach in breast cancer.
High expression of PP2A is associated with cisplatin resistant gastric cancer.
Study identifies Eya3 (show EYA3 Antibodies) as a regulator of PP2A, a major cellular Ser (show SIGLEC1 Antibodies)/Thr (show TRH Antibodies) phosphatase, and uncovers a mechanism of controlling the stability of a critical oncogene (show RAB1A Antibodies), c-Myc (show MYC Antibodies).
Authors demonstrated CFTR (show CFTR Antibodies) and PP2AA interact in the cytosol, resulting in PP2A complex inactivation and increased degradation of PP2A substrates via the lysosomal/proteasome pathway.
Together, the results suggest a complex antagonistic interplay between the control of ARPP-16 (show ARPP19 Antibodies) by MAST3 and PKA that creates a mechanism whereby cAMP mediates PP2A disinhibition.
An imbalanced regulation in protein kinases and protein phosphatases is the direct cause of tau hyperphosphorylation in Alzheimer's disease; GSK-3beta and PP2A are the most implicated. (Review)
Isoliensinine suppresses NF-kappaB (show NFKB1 Antibodies) in hepatocellular carcinoma cells through impairing PP2A/I2PP2A (show SET Antibodies) interaction and stimulating PP2A-dependent p65 (show GORASP1 Antibodies) dephosphorylation at Ser536
BIR (show KCNJ11 Antibodies) domain of XIAP (show XIAP Antibodies) activated the protein phosphatase 2 (PP2A) activity by decreasing the phosphorylation of PP2A at Tyr307 in its catalytic subunit, PP2A-C. Such activated PP2A prevented the deviant phosphorylation and activation of MAPK (show MAPK1 Antibodies) kinases/MAPKs, their downstream effector c-Jun (show JUN Antibodies); and in turn inhibiting transcription of c-Jun (show JUN Antibodies)-regulated miR (show MLXIP Antibodies)-200a
T-type channel signaling is redirected towards the activation of the kinase Akt1 (show AKT1 Antibodies), leading to increased expression of the anti-apoptotic protein survivin, and a decrease in the pro-apoptotic mediator FoxO3A (show FOXO3 Antibodies). Finally, in iPAH cells, Akt1 (show AKT1 Antibodies) is no longer able to regulate caspase 9 (show CASP9 Antibodies) activation, whereas T-type channel overexpression reverses PP2A defect in iPAH cells but reinforces the deleterious effects of Akt1 (show AKT1 Antibodies) activation
Evidence for PPP2R4 as a haploinsufficient tumor suppressor gene, defining a high-penetrance genetic mechanism for PP2A (show PPP2R2B Antibodies) inhibition in human cancer.
data indicate that PTPalpha (show PTPRA Antibodies) and FAK (show PTK2 Antibodies), which are enriched in FAs (show FAS Antibodies), interact with IP3R1 (show ITPR1 Antibodies) at adjacent ER sites to spatially sequester IL-1 (show IL1A Antibodies)-induced Ca(2 (show CA2 Antibodies)+) signalling
findings show that ectopic expression of the phosphotyrosyl phosphatase activator PTPA induces cell death in mammalian cells via a mechanism involving caspase-3 (show CASP3 Antibodies)-dependent apoptosis
oxidative stress regulates the phosphorylation status of nonribosomal rpS3 (show RPS3 Antibodies) by both activating PKCdelta (show PKCd Antibodies) and blocking the PP2A (show PPP2R2B Antibodies) interaction with rpS3 (show RPS3 Antibodies)
results suggested that PPFIA1 (show PPFIA1 Antibodies) functioned with PP2A (show PPP2R2B Antibodies) to promote the dephosphorylation of Kif7 (show KIF7 Antibodies), triggering Kif7 (show KIF7 Antibodies) localization to the tips of primary cilia and promoting Gli (show GLI1 Antibodies) transcriptional activity.
Protein phosphatase 2A is one of the four major Ser/Thr phosphatases and is implicated in the negative control of cell growth and division. Protein phosphatase 2A holoenzymes are heterotrimeric proteins composed of a structural subunit A, a catalytic subunit C, and a regulatory subunit B. The regulatory subunit is encoded by a diverse set of genes that have been grouped into the B/PR55, B'/PR61, and B''/PR72 families. These different regulatory subunits confer distinct enzymatic specificities and intracellular localizations to the holozenzyme. The product of this gene belongs to the B' family. This gene encodes a specific phosphotyrosyl phosphatase activator of the dimeric form of protein phosphatase 2A. Alternative splicing results in multiple transcript variants encoding different isoforms.
PP2A phosphatase activator
, PP2A subunit B' isoform PR53
, phosphotyrosyl phosphatase activator
, protein phosphatase 2A, regulatory subunit B' (PR 53)
, serine/threonine-protein phosphatase 2A activator
, serine/threonine-protein phosphatase 2A regulatory subunit B'
, PP2A, subunit B', PR53 isoform
, serine/threonine-protein phosphatase 2A regulatory subunit 4
, protein tyrosine phosphatase, receptor type, A
, protein phosphatase 2 regulatory subunit 4
, protein phosphatase 2A activator, regulatory subunit 4
, protein phosphatase 2A regulatory subunit 4
, protein phosphatase 2A, regulatory subunit B (PR 53)
, protein phosphatase 2 phosphatase activator L homeolog
, protein phosphatase 2A regulatory subunit 4 L homeolog